<DOC>
	<DOCNO>NCT00295347</DOCNO>
	<brief_summary>The propose research aim compare onset action efficacy fludrocortisone , mineralocorticoid receptor agonist vs. spironolactone , mineralocorticoid antagonist , vs. placebo augmentation selective serotonin reuptake inhibitor ( SSRI ) 65 inpatient severe depression . The study also explore utility hypothalamic-pituitary-adrenal ( HPA ) axis predict treatment response . The study 5-week randomize double-blind trial fludrocortisone vs. spironolactone vs. placebo three year .</brief_summary>
	<brief_title>Mineralocorticoid Receptor Treatment Severe Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Fludrocortisone</mesh_term>
	<criteria>Depressed male female inpatient accord DSMIV Age 18 70 year Minimum 17items Hamilton Depression Score 18 Informed consent sign Relevant medical neurological disorder Pregnancy unsure contraception Relevant psychiatric comorbidity Active alcohol substance abuse/dependance Contraindications SSRI , fludrocortisone , spironolactone Steroid medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>